ClinicalTrials.gg
RecruitingNCT06971354Updated Nov 18, 2026

Treatment of Rumination

An interventional study of Biofeedback and Placebo in Rumination Syndrome, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Background: Rumination syndrome is characterized by the involuntary regurgitation of previously ingested food from the stomach to the mouth, triggered by an unintentional contraction of the abdominal muscles along with simultaneous relaxation of the esophageal sphincters. Based on this mechanism, a biofeedback technique targeting muscular activity has been developed and shown to be effective. However, such techniques are often complex and not widely accessible.

Hypothesis: Rumination can be effectively treated using a simplified, non-instrumental biofeedback technique based on cognitive intervention.

Objective: To evaluate the effectiveness of a non-instrumental biofeedback technique incorporating cognitive intervention for the treatment of rumination. The methodology will build on prior studies, employing a more streamlined biofeedback approach.

Methods: Participants will be assigned to parallel groups with balanced sex distribution. The study will compare responses to biofeedback versus a control intervention. Over a four-week period, each participant will undergo three treatment sessions:

The biofeedback group will be trained to control abdominothoracic musculature through cognitive intervention, supported by original visual materials, both before and after a standardized test meal.

The control group will receive a placebo capsule prior to the test meal, and regurgitation episodes will be recorded.

Following the initial session, biofeedback participants will continue with daily exercises, while control participants will take a placebo with each meal. Treatment response will be assessed by comparing outcomes before and after the intervention. After post-treatment assessment, control group participants will be offered the opportunity to receive biofeedback therapy.

Relevance: This project aims to determine the efficacy of a simplified mechanistic intervention for rumination. If successful, this approach could be adopted in additional healthcare settings.

02

Conditions studied

  • Rumination Syndrome
03

In context

Lead sponsor

Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 276 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rumination syndrome

Exclusion criteria

Exclusion Criteria:

  • Relevant organic diseases
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Biofeedback

    Three biofeedback sessions will be administered during the first three weeks of the intervention period. In each session, participants will receive a standardized meal and undergo training to control abdominal and thoracic muscular activity. This training will be guided by a trained operator using original audiovisual materials and hands-on techniques. Regurgitation episodes will be recorded by participants using an event marker. Following each session, participants will be instructed to perform the same exercises before and after breakfast, lunch, and dinner throughout the four-week intervention period.

    Behavioral: Biofeedback

  • Placebo comparator
    Placebo

    Three treatment sessions will be conducted during the first three weeks of the intervention period. In each session, participants will receive a placebo capsule prior to a standardized meal and will be instructed to record the number of regurgitation episodes using an event marker. Following each session, participants will be asked to take a placebo capsule before each meal throughout the four-week intervention period.

    Dietary Supplement: Placebo

Interventions

  • BehavioralBiofeedback

    Three sessions of biofeedback before and after a standardized meal.

  • Dietary supplementPlacebo

    Three sessions of placebo followed by standardized meal.

06

What researchers measure

Primary outcomes

  1. Number of rumination events after a challenge meal measured by an event marker.

    Each regurgitation event will be registered by the patient using an event marker.

    Time frame: 4 weeks

Secondary outcomes

  1. Number of self perceived rumination events

    Number of rumination events measured by questionnaires administered daily for 7 days before and at the end of treatment.

    Time frame: 4 weeks

  2. Number of rumination events

    Number of rumination events measured by questionnaires administered daily for 7 days, 1 month after treatment.

    Time frame: 1 month

  3. Number of rumination events

    Number of rumination events measured by questionnaires administered daily for 7 days, 3 months after treatment.

    Time frame: 3 months

  4. Number of rumination events

    Number of rumination events measured by questionnaires administered daily for 7 days, 6 months after treatment.

    Time frame: 6 months

  5. Quantity of meal regurgitated

    The quantity of the standardized meal that is regurgitated will be recorded, and the proportion of regurgitated to ingested meal will be calculated.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion May 2026 → Mar 2027 and completion Oct 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
May 2, 2025
Primary completionEst.
Mar 30, 2027was May 2026
CompletionEst.
Jul 30, 2027was Oct 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→Mar 30, 2027
Nov 18, 2026
Study completion
Oct 2026→Jul 30, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion May 2026→Mar 30, 2027
    Study completion Oct 2026→Jul 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06971354
Responsible party
Sponsor
First posted
May 14, 2025
Start date
May 2, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jordi Serra, M.D.
Contact
jordiserra@vallhebron.cat
34 93 274 6259
Gloria Santaliestra
Contact
gloria.santaliestra@vhir.org
34 932746259
Jordi Serra, M.D.
principal investigator · Vall d'Hebron Research Institute, Barcelona, 08035

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion